ProCE Banner Activity

CE / CME

Mastering the Evolving Treatment Landscape in HER2-Positive Breast Cancer: Current Guidance and Future Perspectives

Multimedia
In this on-demand webcast of a live workshop presentation, an expert faculty discusses the evolving treatment landscape in HER2-positive breast cancer.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: March 24, 2022

Expiration: March 23, 2023

No longer available for credit.

Share

Faculty

Aditya Bardia

Aditya Bardia, MD, MPH, FASCO

Program Director, Breast Medical Oncology
Assistant Chief (Translational Research), Division of Hematology-Oncology
Professor of Medicine, Geffen School of Medicine, University of California Los Angeles
Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Center
Los Angeles, California

Claudine Isaacs

Claudine Isaacs, MD

Professor of Medicine and Oncology
Associate Director for Clinical Research
Georgetown University
Washington, DC

David B. Page

David B. Page, MD

Assistant Member, Medical Oncology
Medical Oncologist
Providence Cancer Institute
Providence Health & Services
Portland, Oregon

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Puma Biotechnology, Inc.

Seagen Inc.

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with HER2-positive breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate recent advances and available clinical data to optimally sequence HER2-targeted agents in the treatment of HER2-positive breast cancer from early stage through multiple lines of treatment for MBC
  • Discuss with patients the relative value of different adjuvant and extended adjuvant approaches with sensitivity for the patient’s preferences and risk of progression
  • Plan effective therapy for patients with HER2-positive MBC with or without CNS metastases incorporating existing and emerging targeted treatments
  • Describe the mechanism of action, efficacy results, and toxicity profile of the most newly approved and promising investigational HER2-targeting agents
  • Assess ongoing clinical research studies evaluating novel agents and treatment strategies under development for HER2-positive breast cancer

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Aditya Bardia, MD, MPH, FASCO

Program Director, Breast Medical Oncology
Assistant Chief (Translational Research), Division of Hematology-Oncology
Professor of Medicine, Geffen School of Medicine, University of California Los Angeles
Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Center
Los Angeles, California

Aditya Bardia, MD, MPH, has disclosed that he has received consulting fees from Daiichi Sankyo/AstraZeneca, Foundation Medicine, Genentech, Immunomedics/Gilead Sciences, Lilly, Merck, Novartis, Pfizer, Phillips, Radius Health, and Sanofi and funds for research support from Daiichi Sankyo/AstraZeneca, Genentech, Immunomedics/Gilead Sciences, Lilly, Merck, Natera, Novartis, Pfizer, Radium Health, and Sanofi.

Claudine Isaacs, MD

Professor of Medicine and Oncology
Associate Director for Clinical Research
Georgetown University
Washington, DC

Claudine Isaacs, MD, has disclosed that she has received consulting fees from Amerisource Bergen, AstraZeneca, Biotheranostics, Eisai, Genentech, Immunomedics, Novartis, Pfizer, Puma, Sanofi, and Seagen.

Faculty Disclosure

Primary Author

David B. Page, MD

Assistant Member, Medical Oncology
Medical Oncologist
Providence Cancer Institute
Providence Health & Services
Portland, Oregon

David B. Page, MD, has disclosed that he had received consulting fees from Biotheranostics, Bristol-Myers Squibb, Brooklyn Immunotherapeutics, Genentech, Lilly, Merck Sharpe and Dohme, Novartis, Puma, Sanofi, and WindMIL.

Staff Disclosure

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason Everly has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Kristi K. Orbaugh, MSN, RNP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physician
A Partner of MD Anderson
Indianapolis, Indiana

Kristi Orbaugh, MSN, NP, AOCNP has disclosed that she has served as a speaker for AstraZeneca, Bristol-Myers Squibb, DSI, Gilead Sciences, Lilly, Morphosys, Pfizer, Regeneron, and Sanofi.

Anna Poppa,

Managing Editor, HIV
Clinical Care Options, LLC

Anna Poppa has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.01 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-088-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 24, 2022, through March 23, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners in selecting individualized treatment for patients with HER2-positive breast cancer.